Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBLG Bone Biologics	$2.20 +1.4%	$3.27	$2.08 ▼ $16.50	$3.95M	0.66	45,932 shs	19,252 shs
CHEK Check-Cap	$0.64 +0.8%	$0.73	$0.56 ▼ $3.04	$3.77M	0.19	25,788 shs	32,408 shs
PTHL Pheton	$0.60 +0.2%	$13.11	$0.51 ▼ $32.00	$3.95M	N/A	3.27 million shs	433,541 shs
QNRX Quoin Pharmaceuticals	$7.28 -0.1%	$8.19	$5.01 ▼ $54.95	$4.24M	1.44	4,512 shs	2,465 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBLG Bone Biologics	+1.38%	0.00%	-28.10%	-55.28%	-76.79%
CHEK Check-Cap	+1.13%	-3.13%	-15.55%	-24.00%	-66.62%
PTHL Pheton	+0.20%	-5.17%	-97.45%	-90.90%	+59,999,900.00%
QNRX Quoin Pharmaceuticals	+0.40%	-2.74%	-13.39%	-18.26%	-64.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBLG Bone Biologics	0.7283 of 5 stars	0.0	5.0	0.0	0.0	0.0	0.0	1.3
CHEK Check-Cap	0.6351 of 5 stars	0.0	3.0	0.0	0.0	2.8	0.0	0.6
PTHL Pheton	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	0.8148 of 5 stars	0.0	4.0	0.0	0.0	1.8	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBLG Bone Biologics	N/A	N/A	N/A
CHEK Check-Cap	N/A	N/A	N/A
PTHL Pheton	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBLG Bone Biologics	N/A	N/A	N/A	N/A	$3.67 per share	N/A
CHEK Check-Cap	N/A	N/A	N/A	N/A	$4.05 per share	N/A
PTHL Pheton	$450K	8.77	N/A	N/A	$0.94 per share	0.64
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	$4.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBLG Bone Biologics	-$4.11M	N/A	0.00	N/A	N/A	N/A	-100.58%	-93.31%	N/A
CHEK Check-Cap	-$17.57M	-$3.00	N/A	∞	N/A	N/A	N/A	N/A	N/A
PTHL Pheton	-$660K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	-$8.96M	-$41.45	0.00	N/A	N/A	N/A	-210.50%	-99.41%	11/6/2025 (Estimated)

Latest BBLG, PTHL, QNRX, and CHEK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	BBLG Bone Biologics	-$0.58	-$1.33	-$0.75	-$1.33	N/A	N/A
8/7/2025	Q2 2025	QNRX Quoin Pharmaceuticals	-$6.83	-$6.28	+$0.55	-$6.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBLG Bone Biologics	N/A	N/A	N/A	N/A	N/A
CHEK Check-Cap	N/A	N/A	N/A	N/A	N/A
PTHL Pheton	N/A	N/A	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBLG Bone Biologics	N/A	17.25	12.60
CHEK Check-Cap	N/A	N/A	N/A
PTHL Pheton	N/A	12.39	12.17
QNRX Quoin Pharmaceuticals	N/A	1.96	1.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBLG Bone Biologics	34.30%
CHEK Check-Cap	1.07%
PTHL Pheton	N/A
QNRX Quoin Pharmaceuticals	8.63%

Insider Ownership

Company	Insider Ownership
BBLG Bone Biologics	6.10%
CHEK Check-Cap	0.48%
PTHL Pheton	N/A
QNRX Quoin Pharmaceuticals	13.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBLG Bone Biologics	2	1.80 million	1.69 million	Not Optionable
CHEK Check-Cap	80	5.85 million	5.82 million	Not Optionable
PTHL Pheton	11	6.58 million	N/A	N/A
QNRX Quoin Pharmaceuticals	4	590,000	509,000	Not Optionable

BBLG, PTHL, QNRX, and CHEK Headlines

Recent News About These Companies

Quoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome

August 21 at 6:45 PM | markets.businessinsider.com

Head-To-Head Review: Quoin Pharmaceuticals (NASDAQ:QNRX) and Rafael (NYSE:RFL)

August 20 at 2:27 AM | americanbankingnews.com

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

August 18, 2025 | finanznachrichten.de

Quoin Pharmaceuticals appoints Lawlor as Chief Financial Officer

August 18, 2025 | msn.com

Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

August 18, 2025 | globenewswire.com

Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton

August 12, 2025 | globenewswire.com

QNRX: Recent FDA & EMA Designations for QRX003 Potentially Could Accelerate Timeline

August 8, 2025 | finance.yahoo.com

Quoin (QNRX) Q2 Loss Beats Estimates

August 7, 2025 | fool.com

Quoin Pharmaceuticals stock rises after positive clinical updates

July 31, 2025 | investing.com

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Product Portfolio Update

July 29, 2025 | finanznachrichten.de

Quoin Pharmaceuticals Provides Product Portfolio Update

July 29, 2025 | globenewswire.com

Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases - Morningstar

June 27, 2025 | morningstar.comM

Quoin Pharmaceuticals Releases New Episode of NETHERTON NOW Featuring Expert Insights on Netherton Syndrome - Nasdaq

June 27, 2025 | nasdaq.com

QNRX - Quoin Pharmaceuticals Ltd ADR Executives - Morningstar

June 26, 2025 | morningstar.comM

Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases

June 26, 2025 | finance.yahoo.com

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome - Yahoo Finance

June 25, 2025 | finance.yahoo.com

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome

June 24, 2025 | tmcnet.com

Quoin Pharmaceuticals, Ltd. (QNRX) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

QNRX: With FDA Clearance to Initiate 2nd NS Whole Body Study for QRX003, Clinical Activities Expand Further

May 29, 2025 | finance.yahoo.com

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

May 22, 2025 | manilatimes.netM

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBLG, PTHL, QNRX, and CHEK Company Descriptions

Bone Biologics NASDAQ:BBLG

$2.20 +0.03 (+1.38%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.20 +0.00 (+0.23%)

As of 08/22/2025 06:43 PM Eastern

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Check-Cap NASDAQ:CHEK

$0.64 +0.00 (+0.75%)

Closing price 08/22/2025 03:58 PM Eastern

Extended Trading

$0.65 +0.00 (+0.43%)

As of 08/22/2025 05:04 PM Eastern

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.

Pheton NASDAQ:PTHL

$0.60 +0.00 (+0.20%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.59 -0.01 (-1.67%)

As of 08/22/2025 07:39 PM Eastern

Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.

Quoin Pharmaceuticals NASDAQ:QNRX

$7.28 -0.01 (-0.07%)

Closing price 08/22/2025 03:57 PM Eastern

Extended Trading

$7.15 -0.12 (-1.70%)

As of 08/22/2025 05:58 PM Eastern

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time